Beneficial drugs for liver diseases

被引:115
作者
Muriel, Pablo [1 ]
Rivera-Espinoza, Yadira [2 ]
机构
[1] Cinvestav IPN, Dept Farmacol, Mexico City 07000, DF, Mexico
[2] Inst Politecn Nacl, Escuela Nacl Ciencias Biol, Dept Grad & Invest Alimentos, Mexico City 11340, DF, Mexico
关键词
colchicine; curcumin; interferons; nitric oxide; resveratrol; silymarin; S-adenosyl-L-methionine; thalidomide; liver damage;
D O I
10.1002/jat.1310
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Liver diseases are a major problem of worldwide proportions. However, the number of drugs actually used successfully in humans is very small. In this review some of the most promising/studied drugs utilized for liver diseases were chosen and analysed critically from the basic to the clinical point of view. Antiviral agents are not discussed because excellent reviews have appeared on this topic. The compounds/preparations described herein are, alphabetically: colchicine, corticosteroids, curcumin, glycyrrhizin, interferons (for their antifibrotic properties), Liv 52, nitric oxide, resveratrol, silymarin, sulfoadenosyltnethionine, and thalidomide. Colchicine and corticosteroids have been studied extensively in animals and humans; most clinical studies suggest that these compounds are not useful in the treatment of liver diseases. Glycyrrhizin is an herbal medicine with several components that has interesting hepatoprotective properties in patients with subacute liver failure but deserves more prospective controlled trials. Interferon has shown interesting antifibrotic properties in animals and humans; prospective studies on their antifibrotic/fibrolytic activity are required. Curcumin, resveratrol and thalidomide are very attractive newly discovered protective and curative compounds on experimental hepatic diseases. Their mechanism of action is associated with the ability to down-regulate NF-kappa B and to decrease pronecrotic and profibrotic cytokines. Unfortunately, clinical studies are lacking. Sulfoadenosylmethionine and silymarin are also promising drugs utilized mainly in cholestasis but the benefits can be expanded if more controlled trials are performed. The future is to carry out controlled prospective double-blind multicenter studies with the newly discovered drugs with proven beneficial effects on animals. Fundamental hepatobiology should also be encouraged. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 140 条
  • [1] INTERFERON INDUCTION BY GLYCYRRHIZIN AND GLYCYRRHETINIC ACID IN MICE
    ABE, N
    EBINA, T
    ISHIDA, N
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 1982, 26 (06) : 535 - 539
  • [2] Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages
    Abe, Y
    Hashimoto, S
    Horie, T
    [J]. PHARMACOLOGICAL RESEARCH, 1999, 39 (01) : 41 - 47
  • [3] Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
  • [4] AGGARWAL BB, 2007, MED AROMATIC PLANTS, V45, P297
  • [5] PHARMACOLOGY OF CURCUMA-LONGA
    AMMON, HPT
    WAHL, MA
    [J]. PLANTA MEDICA, 1991, 57 (01) : 1 - 7
  • [6] Protective effect of resveratrol against oxidative stress in cholestasis
    Ara, C
    Kirimlioglu, H
    Karabulut, AB
    Coban, S
    Ay, S
    Harputluoglu, M
    Kirimlioglu, V
    Yilmaz, S
    [J]. JOURNAL OF SURGICAL RESEARCH, 2005, 127 (02) : 112 - 117
  • [7] Baker Danial E, 2003, Rev Gastroenterol Disord, V3, P93
  • [8] Prevention of liver cirrhosis in rats by curcumin
    Bruck, Rafael
    Ashkenazi, Michal
    Weiss, Sigal
    Goldiner, Ilana
    Shapiro, Haim
    Aeed, Hussein
    Genina, Olga
    Helpern, Zamir
    Pines, Mark
    [J]. LIVER INTERNATIONAL, 2007, 27 (03) : 373 - 383
  • [9] Castro V, 1996, J APPL TOXICOL, V16, P269, DOI 10.1002/(SICI)1099-1263(199605)16:3<269::AID-JAT346>3.0.CO
  • [10] 2-Y